Physician profile
Stephen Grelecki
NPI 1508838665
$4,263.00
in general payments reported to CMS, 2019-2025
17 companies · $764 in 2025
The $764 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $419 · 2021: $536 · 2022: $673 · 2023: $637 · 2024: $510 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,317.71 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $879.79 | 2019-2025 | Invega Trinza, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $375.58 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $298.97 | 2019-2023 | Austedo |
| Alkermes, INC. | $287.55 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Indivior INC. | $235.11 | 2019-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.98 | 2021-2025 | Caplyta |
| Lundbeck LLC | $159.24 | 2021-2024 | Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $123.66 | 2020-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $122.30 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $81.00 | 2019-2022 | |
| Allergan, INC. | $59.51 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $57.41 | 2020-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $32.20 | 2020 | |
| Supernus Pharmaceuticals, INC. | $28.67 | 2024-2025 | Qelbree |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.47 | 2023 | Abilify Maintena |
| Eisai INC. | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Grelecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.